PRescriptiOn PattERns Of Oral Anticoagulants

Atrial Fibrillation Clinical Trial

— PROPER  

Official title:

PRescriptiOn PattERns Of Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Single Center Experience From Turkey (PROPER)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02366338
• Other study ID #: PROPER
• Status: Completed
• Phase: N/A
• First received: February 8, 2015
• Last updated: April 30, 2015
• Start date: August 2014
• Est. completion date: November 2014

Study information

• Verified date: April 2015
• Source: Mugla Sitki Koçman University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ethics Committee
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Atrial fibrillation is the major cause of acute ischemic stroke. The risk of stroke was shown to decline by oral anticoagulant therapy. The investigators intended to evaluate appropriate use of anticoagulants in non-valvular AF patients.

Description:

Atrial fibrillation, the most common sustained arrhythmia, is the major cause of acute ischemic stroke. The prognosis of ischemic stroke associated with atrial fibrillation (AF) tends to have a worse prognosis for recovery compared with other ischemic stroke subtypes. The risk of stroke was shown to decline to 68% by oral anticoagulant (OAC) therapy.The investigators have evaluated appropriate use of anticoagulants in non-valvular AF patients. Appropriate use of oral anticoagulants was assessed by Medication Appropriateness Index (MAI). The MAI consists of 10 criteias namely, indication, choice, dosage, modalities and practicability of administration, drug-drug interactions, drug-disease interactions, duplication, duration, and cost-effectiveness. The tenth criteria was not evaluated because of limited data regarding cost-effectiveness of the drugs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 148
• Est. completion date: November 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Non valbular AF >18 years

Exclusion Criteria:

• Not currently receiving anticoagulant

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Mugla Sitki Koçman University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With at Least One Inappropriate MAI Criterion	Appropriateness of oral anticoagulants was evaluated by adapted versions of the MAI	1 day	No